Select therapeutic use:
Indications for DETROL:
Overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.
2mg twice daily; may decrease to 1mg twice daily. Concomitant strong CYP3A4 inhibitors (ketoconazole, itraconazole, miconazole, clarithromycin, erythromycin, cyclosporine, vinblastine), or significant renal or hepatic dysfunction: 1mg twice daily.
Urinary or gastric retention. Uncontrolled narrow-angle glaucoma. Fesoterodine fumarate allergy.
Bladder outflow obstruction. GI obstruction (eg, pyloric stenosis). Decreased GI motility. Discontinue if angioedema occurs. Monitor for anticholinergic CNS effects (esp. when starting treatment and after dose increases). Narrow-angle glaucoma. Myasthenia gravis. History of QT prolongation. Pregnancy. Nursing mothers: not recommended.
Plasma levels increased by CYP3A4 inhibitors (see Adult dose). Caution with Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmics. Additive anticholinergic effects with other anticholinergics.
Dry mouth/eyes, headache, constipation, abdominal pain, dyspepsia, fatigue, dizziness, somnolence, sinusitis, abnormal vision, anxiety, dysuria, other anticholinergic effects; anaphylaxis, angioedema.
Hepatic (CYP2D6, 3A4).
Renal (primarily), fecal.
LA—30, 90, 500; Tabs—60, 500